Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.